KRMD KORU Medical Systems, Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 704440 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY18.4%
TTM net income YoY77.8%
TTM EPS YoY92.9%
Revenue 3-yr CAGR17.3%
Net income 3-yr CAGR—
Margins
Gross margin63.6%
Operating margin-1.3%
Net margin-1.8%
FCF margin-0.8%
EBITDA margin0.4%
Returns
ROE-4.6%
ROA-2.9%
ROIC (approx.)-4.7%
Asset turnover1.66x
Leverage & solvency
Liabilities / assets32.6%
Debt / equity0.00x
Current ratio2.97x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-0.54x
Accruals ratio-4.5%
Payout ratio—
Capex / revenue1.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $41.13M | $33.65M |
| Cost of revenue | $15.52M | $12.31M |
| Gross profit | $25.60M | $21.33M |
| R&D expense | $4.39M | $5.26M |
| SG&A expense | $23.38M | $21.63M |
| Operating income | -$2.97M | -$6.45M |
| Pretax income | -$2.62M | -$6.06M |
| Income tax | $21,890 | $2,893 |
| Net income | -$2.64M | -$6.07M |
| EBITDA | -$2.16M | -$5.56M |
| EPS (basic) | -0.06 | -0.13 |
| EPS (diluted) | -0.06 | -0.13 |
| Weighted avg. shares (diluted) | 46.19M | 45.80M |
| Balance sheet | ||
| Cash & equivalents | $8.87M | $9.58M |
| Receivables | $5.97M | $5.72M |
| Inventory | $3.68M | $2.80M |
| Current assets | $19.99M | $19.13M |
| PP&E, net | $4.47M | $4.29M |
| Intangibles | $684,841 | $730,279 |
| Total assets | $28.20M | $27.22M |
| Current liabilities | $8.19M | $7.20M |
| Total liabilities | $11.15M | $10.40M |
| Shareholders' equity | $17.05M | $16.81M |
| Shares outstanding | 46.37M | 45.96M |
| Cash flow statement | ||
| Operating cash flow | $462,405 | -$319,718 |
| Capital expenditure | $932,517 | $1.30M |
| Free cash flow | -$470,112 | -$1.62M |
| Investing cash flow | -$949,790 | -$1.33M |
| Financing cash flow | -$221,350 | -$248,533 |
| Depreciation & amortization | $810,500 | $888,473 |
| Stock-based compensation | $2.71M | $2.62M |
Free plan shows the latest 2 periods; Pro shows all 15 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.